A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
The length of time during and after the treatment that participants in the study live without the disease getting worse
Up to 1 year
No
Ye Hua, MD
Study Director
Celgene Corporation
United States: Food and Drug Administration
CC-4047-MM-007
NCT01734928
December 2012
January 2017
Name | Location |
---|---|
Celgene Study Site | West Palm Beach, Florida 33401 |
Celgene Study Site | Marietta, Georgia 30060 |
Celgene Study Site | Baltimore, Maryland 21215 |
Celgene Study Site | St. Louis, Missouri 63110 |
Celgene Study Site | Omaha, Nebraska 68198 |
Celgene Study Site | Hackensack, New Jersey 07601 |
Celgene Study Site | Sioux Falls, South Dakota 57105 |
Celgene Study Site | Dallas, Texas 75390 |
Celgene Study Site | Milwaukee, Wisconsin 53226 |
Celgene Study Site | Washington, District of Columbia 20037 |
Celgene Study Site | New Orleans, Louisiana 70112 |
Celgene Study Site | Brewer, Maine 04412 |
Celgene Study Site | Billings, Montana 59102 |
Celgene Study Site | Canton, Ohio 44718 |
Celgene Study Site | Nashville, Tennessee 37232 |